Clinical Trial Update: Study of Transitioning From Alendronate to Denosumab [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating transitioning from alendronate to denosumab for postmenopausal osteoporosis, with results posted in August 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Denosumab (denosumab)
• alendronate (alendronate)

Snippet

Sponsor: Amgen | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2010-08-03